Abolishing the 1-year rule: How much evidence will be enough?

Movement Disorders

Volumn 31, Issue 11, 2016, Pages 1623-1627

  Postuma, Ronald B ^a   Berg, Daniela ^b   Stern, Matthew ^c   Poewe, Werner ^d   Olanow, C Warren ^e   Oertel, Wolfgang ^f   Marek, Kenneth ^g   Litvan, Irene ^h   Lang, Anthony E ⁱ   Halliday, Glenda ^j   Goetz, Christopher G ^k   Gasser, Thomas ^b   Dubois, Bruno ^l   Chan, Piu ^m   Bloem, Bastiaan R ⁿ   Adler, Charles H ^o   Deuschl, Günther ^p  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Penn Neurological Institute   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e MOUNT SINAI HOSPITAL   (United States)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ TORONTO WESTERN HOSPITAL   (Canada)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m CAPITAL MEDICAL UNIVERSITY   (China)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^o MAYO CLINIC   (United States)

^p UNIVERSITY OF KIEL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIFFUSE LEWY BODY DISEASE; HUMAN; MEDICAL DECISION MAKING; PARKINSON DISEASE; PRIORITY JOURNAL; MEDICAL SOCIETY; PRACTICE GUIDELINE; STANDARDS;

HUMANS; LEWY BODY DISEASE; PARKINSON DISEASE; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 85014767759     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26796     Document Type: Article

References (20)

1. Berg D, Postuma RB, Bloem B, et al. Time to redefine PD?. Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 2014;29(4):454–462.
2. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30(12):1591–1600.
3. Berg D, Postuma RB, Adler CH, et al. MDS Research criteria for prodromal Parkinson's disease. Mov Disord 2015;30(12):1600–1611.
4. Boeve B, Dickson D, Duda JE, et al. Arguing Against the Proposed Definition Changes of PD. Mov Disord 2016; [Epub ahead of print].
5. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree—a new disease? Clin Neuropathol 1984;3(5):185–192.
6. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47(5):1113–1124.
7. Domellof ME, Ekman U, Forsgren L, Elgh E. Cognitive function in the early phase of Parkinson's disease, a five-year follow-up. Acta Neurol Scand 2015;132(2):79–88.
8. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134(Pt 5):1493–505.
9. Anang JB, Gagnon JF, Bertrand JA, et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 2014;83(14):1253–1260.
10. Chahine LM, Weintraub D, Hawkins KA, et al. Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. Mov Disord 2016;31(1):86–94.
11. Guella I, Evans DM, Szu-Tu C, et al. alpha-synuclein genetic variability: a biomarker for dementia in Parkinson disease. Ann Neurol 2016;79(6):991–999.
12. Kalia LV, Lang AE, Hazrati LN, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 2015;72(1):100–105.
13. Gan-Or Z, Mirelman A, Postuma RB, et al. GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder. Ann Clin Transl Neurol 2015;2(9):941–945.
14. Gomperts SN, Locascio JJ, Rentz D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013;80(1):85–91.
15. Gibbons CH, Freeman R. Clinical implications of delayed orthostatic hypotension: a 10-year follow-up study. Neurology 2015;85(16):1362–1367.
16. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68(11):812–819.
17. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet 2015;386(10004):1683–1697.
18. Nomura T, Inoue Y, Kagimura T, Nakashima K. Clinical significance of REM sleep behavior disorder in Parkinson's disease. Sleep Med 2013;14(2):131–135.
19. Romenets SR, Wolfson C, Galatas C, et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord 2012;18(1):54–58.
20. Rios Romenets S, Creti L, Fichten C, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study. Parkinsonism Relat Disord 2013;19(7):670–675.